Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Recruiting 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2

Conditions

Carcinoma, Non-Small-Cell Lung 35Lung Neoplasms 19Squamous Cell Carcinoma of Head and Neck 18Oropharyngeal Neoplasms 8Urinary Bladder Neoplasms 7Uterine Cervical Neoplasms 6Parkinson Disease 4, Autosomal Dominant Lewy Body 6Pancreatic Neoplasms 5Endometrial Neoplasms 5Colorectal Neoplasms 5Cholangiocarcinoma 5Carcinoma 5Biliary Tract Neoplasms 5Neoplasms 4Neoplasm Metastasis 4Nasopharyngeal Carcinoma 4Mouth Neoplasms 4Head and Neck Neoplasms 4Carcinoma, Squamous Cell 4Mesothelioma, Malignant 3Laryngeal Neoplasms 3Esophageal Squamous Cell Carcinoma 3Triple Negative Breast Neoplasms 2Tongue Neoplasms 2Small Cell Lung Carcinoma 2Salivary Gland Neoplasms 2Rectal Neoplasms 2Ovarian Neoplasms 2Osteosarcoma 2Non-squamous Non-small Cell Lung Cancer 2

Interventions

X-Rays 5Phantoms, Imaging 5Magnetic Resonance Spectroscopy 5Nuclear Medicine Department, Hospital 4Cyclophosphamide 4fludarabine 3Specimen Handling 3Doxorubicin 3Biopsy 3ulixertinib 2tipifarnib 2selpercatinib 2olaparib 2larotrectinib 2ivosidenib 2ensartinib 2cabozantinib 2Methotrexate 2Mesna 2Ifosfamide 2Gemcitabine 2Eflornithine 2Cisplatin 2tazemetostat 1talazoparib 1selinexor 1pazopanib 1palbociclib 1mifamurtide 1merphos 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Osteosarcoma × Cisplatin × 30 days × Clear all
NCT05691478 2026-06-03

A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma

National Cancer Institute (NCI)

Phase 2/3 Recruiting
1,122 enrolled
Sarcoma

Osteosarcoma

NCT07321912 2026-05-26

Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma

Milton S. Hershey Medical Center

Phase 2 Recruiting
406 enrolled
Sarcoma

Sarcoma, Ewing, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡